

Welcome to Everest Organics Limited





Disclaimer

Everest Organics Limited may from time to time make written and oral forward-looking statements in addition to statements contained in the company's filing with BSE Limited (BSE) and other reports to share holders. The company does not undertake to update any person any forward-looking statement that may be made from time to time by or on behalf of Everest Organics Limited.

This presentation is for general information only without regards to any specific objectives. This presentation may contain statements that constitute forward looking statements involving known and unknown risk, uncertainties and other factors which may cause the actual results, financial conditions, performance or achievements vulnerable.

All Information contained in this presentation has been prepared solely by Everest Organics Limited. It does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith.



About Us

- Everest Organics Limited is a Company incorporated in the year 1995 as a public listed company engaged in the business of Manufacturing and sale of Active Pharmaceutical Ingredients and Intermediates.
- > Dr. Sri Kakarlapudi Srihari Raju, (MD, MBBS), is a Promoter and Managing Director of the Company.
- Everest is in the business of Manufacturing of API's for more then two decades.
- Our API manufacturing site is located in Sangareddy District, Telangana, factory area occupied in a total area of 33 acres of land of which 10 acres of land covers the infrastructure and remaining 23 acres of land is covered with green belt.
- Due to its strong R & D Capabilities, Everest offer various kinds of services in addition to supply of APIs. It undertake long term contracts for manufacturing intermediates and development of new APIs.



Business Overview

Products and Development

- The state of art USFDA facility at a single location has nearly 15% of global prazole market share. The portfolio has diversified beyond prazoles and includes Omeprazole, Esomeprazole, Pantoprazole, Fenofibrate, Dexlansoprazole, Rabeprazole, Itraconazole, Rivaroxaban and Febuxostat.
- Strong R&D Capabilities leads to enhancement of portfolio.
- Enhanced focus on anti-viral segment, Oseltamivir (under commercial stage) and Remdesivir (under lab scale trial).
- Supply to more than 40 countries, strong presence in South Asian countries.
- In the process of registering products in China.
- Exploring Regulated market opportunities in US and EU.
- EC clearance received for 3X expansion in capacity. This would also enhance R&D capabilities.



Business Overview

Manufacturing Capability

- The plant is approved by cGMP, cGLP, WHO GMP and global regulatory authorities such as USFDA.
- Certified by:
 - **❖** ISO 9001:2015;
 - **❖** EMS 14001:2015;
 - ❖ OHSAS 18001:2007.

Financial Snapshot

- FY20 Revenues of Rs. 168 Cr.
- FY20 PAT of Rs. 10.9 Cr.

Shareholding as of March 2020

- Total Share Capital: 8 Cr.
- Promoters hold 73.79% and Public Holding 26.21%.



Financial Performance Income Growth

Particulars	2017-18	2018-19	2019-20
Total Income	112,87,30,996	156,39,30,473	168,66,51,691
PBIDT	7,78,23,388	18,37,64,988	20,16,65,268
PAT	2,58,44,249	7,50,85,785	10,89,66,877
EPS	3.23	9.39	13.62

5 YEARS FINANCIAL GROWTH			
S. No.	Particulars	Percentage	
1.	Sale growth	20%	
2.	Profit growth	60%	
3.	Return on equity	22%	







Credit Rating

Particulars	2016-17	2017-18	2018-19	2019-20
Agency	CRISIL	ICRA	ICRA	Brickwork Rating
Fund Based-Term Loan	B-/Stable	BB-	BB	BWR BBB-/Stable
Non-Fund Based Limits	A4	A4	A4+	BWR A3
Fund Based Limits	B-/Stable/A4	BB-/A4	BB/A4+	BWR A3





Value Added Chain (Green Initiative)

Waste to Value Added Product

Ammonium Sulphate, Calcium Sulphate, Calcium Nitrate, Disodium Phosphate, Potasium Nitrate, Tri Sodium Phosphate, Sodium Di Acetate, Sodium Acetate, Sodium Sulphate, Sodium Nitrate, Potasium Chloride.

- Derived from primary waste.
- Using in-house developed technology.
- Green initiative nature friendly.
- > Zero waste discharge policy.
- Catering to quality conscious clientele.



Key Products

Name of the Product	Grade	Therapeutic Category
Omeprazole	IP/BP/USP/ Ph.Eur	Anti ulcerant
Esomeprazole Magnesium Trihydrate	IP/BP/USP/Ph.Eur	Anti ulcerant
Pantoprazole Sodium Sesquihydrate	IP/BP/ Ph.Eur	Anti ulcerant
Pantoprazole Sodium	USP	Anti ulcerant
Omeprazole Magnesium	USP	Anti ulcerant
Esomeprazole Sodium	IH	Anti ulcerant
Esomeprazole Magnesium Dihydrate	IH	Anti ulcerant
Omeprazole Sodium	Ph.Eur	Anti ulcerant
Fenofibrate	IP/BP/USP/Ph.Eur	Anti hyper lipidemic
Dexlansoprazole	INH	Gastroesophageal reflux disease
Rabeprazole Sodium	IP/EP	Gastro resistant
Itraconazole	Ph.Eur/BP	Anti fungal
Rivaroxaban	IH	Anticoagulant
Febuxostat	IH	antihyperuricemic agent
Oseltamivir	USP	Covid Segment



List of Intermediates

Name of the Product	Related API's
2-Chloro methyl-3,5-Dimethyl-4-Methoxy Pyridine Hydrochloride (Chloro compound)	Omeprazole
2-Mercapto-5-Methoxy Benzimidazole	Omeprazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]thio]-1H-Benzimidazole (Sulphide)	Omeprazole
2-Chloromethyl-3,4 dimethoxy pyridine hydrochloride (Chloro compound)	Pantoprazole
5(Di flouro Methoxy)-2-[[(3,4-dimethoxy pyridin-2-yl) methyl] thio]-1H-Benzimidazole (Sulphide)	Pantoprazole
Oseltamivir Epoxide	Oseltamivir



Future Growth Plan

COVID - 19

Enhanced Focus on Antiviral Segments, Covid-19 and Future virus related products.

R & D Capabilities

Expansion programme for R & D.

Forward Integration

Forward Integration into Pellets and Lyophilization

Strategy in Place for Next Growth Phase

Plans to enter into
Phytochemical-immune segment
with Curcumin and Piperine
Energy Immune Boosters.

Everest Organics Limited

Diversified Geographic Presence

Everest has global presence of over more than 40 countries.

Development Plan

Develop and Manufacture vitamin

Volume Growth

EC clearance received for expansion of current capacity by three fold.

Future Market


Future Focus is China, US and EU
Market
Privilege Exports of API to China



Organization Chart



EVEREST ORGANICS LIMITED QUALITY ASSURANCE DEPARTMENT ORGANIZATION CHART



CONTROLLED COPY



Contact Person

Ms. Rekha Singh Company Secretary Contact No. +91-40-40028838 E-mail: eolcs0405@gmail.com

IR/ Legal Consultant: VB ADVISORY E-mail: vbadvisory123@gmail.com



Factory Site





Thank You